



RECEIVED BY THE UNITED STATES  
PATENT AND TRADEMARK OFFICE for the PCT  
Paper: Transmittal Letter (in duplicate with Express  
Mail Stamp) to the United States Designated/Elected  
Office Concerning a Filing under 35 U.S.C. 371; courtesy  
copy of International Application; copy of Search Report;  
Unexecuted Combined Declaration; copy of Preliminary  
Examination Report; Information Disclosure Statement;  
credit card payment form for \$906.00 for filing fee; all  
via return receipt Express Mail #EL777534155US

Applicant(s):  
Serial No.:  
Filed:  
Docket No.:  
Date Sent:

Brian J. Nickoloff  
PCT/US99/14549  
Herewith  
ISPH-0531  
January 5, 2001


09/743163

525 Rec'd PCT/PTO 05 JAN 2001



Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, NJ 08053

08053+2141



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0531

Inventors: BRIAN J. NICKOLOFF

Serial No.: NOT YET ASSIGNED

Filing Date: HEREWITH

Examiner: NOT YET ASSIGNED

Group Art Unit: NOT YET ASSIGNED

Title: METHOD OF TREATING DISORDERS BY  
MODULATING THE INTERACTION OF NATURAL  
KILLER RECEPTORS ON T CELLS WITH THEIR  
RESPECTIVE LIGANDS

"Express Mail" Label No. EL777534155US  
Date of Deposit 5 January 2001

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
Assistant Commissioner for Patents, Box PCT,  
Washington, D.C. 20231.

By Deborah Ehret  
Typed Name: Deborah Ehret

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- ( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- ( ) Certification in Accordance with §1.97(e) is set forth below; or
- ( ) The fee of \$240.00 as set forth in §1.17(p) is attached.
- ( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(xx) All listed references are in the English language.

Respectfully submitted,



Kathleen A. Tyrrell  
Registration No. 38,350

Date: January 5, 2001

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515

<b>Form PTO-1449 Modified</b>  List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0531	Serial No. NOT YET ASSIGNED
	Applicant BRIAN J. NICKOLOFF	
	Filing Date HEREWITH	Group NOT YET ASSIGNED

**U. S. PATENT DOCUMENTS**

Examiner		Document	Date	Name	Class	Subclass
	AA	5,028,424	7-2-91	Evans et al.		
	AB	5,185,430	2-9-93	Evans et al.		
	AC	5,770,387	6-23-98	Litwin et al.		

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation YES NO

EXAMINER	DATE CONSIDERED
----------	-----------------

<b>Form PTO-1449 Modified</b>  List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce		Docket No. <b>ISPH-0531</b>	Serial No. <b>NOT YET ASSIGNED</b>
		Applicant <b>BRIAN J. NICKOLOFF</b>	
		Filing Date <b>HEREWITH</b>	Group <b>NOT YET ASSIGNED</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	AA	Carbone et al., "Natural Killer Clones Recognize Specific Soluble HLA Class I Molecules", <i>1996 European Journal of Immunology</i> 26(3):683-689	
	AB	Lazetic et al., "Human Natural Killer Cell Receptors Involved In MHC Class I Recognition Are Disulfied-Linked Heterodimers of CD94 and NKG2 Subunits", <i>1996 Journal of Immunology</i> 157:4741-4745	
	AC	Lopez-Botet et al., "The CD94/NKG2 C-Type Lectin Receptor", <i>1997 Complex. Immunological Research</i> 16(2):175-185	
	AD	Majewski et al., "Defective Natural Killer-And Killer-Cell Activity Associated With Increased Polymorphonuclear Leukocyte Adherence In Psoriasis", <i>1986 Arch. Dermatol. Research</i> 278:264-269	
	AE	Phillips, J.H., et al., "CD94 and a Novel Associated Protein (94AP) Form a NK Cell Receptor Involved in the Recognition of HLA-A, HLA-B, and HLA-C Allotypes" <i>1996 Immunity</i> 5:163-172	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	